Understanding CML biology as well as BCR-ABL structure and function led to the development and approval in the late 1990s early 2000s of the orally bioavailable first-generation ATP-competitive tyrosine kinase inhibitor (TKI) imatinib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.